LENSAR (NASDAQ:LNSR) Stock Rating Lowered by Wall Street Zen

LENSAR (NASDAQ:LNSR) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of LENSAR from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Loop Capital set a $11.00 price target on LENSAR in a research note on Monday, September 28th. BTIG Research lifted their price target on LENSAR from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Lake Street Capital reissued a “buy” rating and issued a $13.00 price objective on shares of LENSAR in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, LENSAR presently has a consensus rating of “Hold” and an average price target of $11.33.

LENSAR Price Performance

Shares of LNSR opened at $6.75 on Friday. The company has a market capitalization of $82.96 million, a price-to-earnings ratio of -20.45 and a beta of 0.95. LENSAR has a 52-week low of $4.95 and a 52-week high of $12.94. The stock has a 50 day moving average price of $7.29 and a 200 day moving average price of $6.32.

LENSAR (NASDAQ:LNSR) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26. The company had revenue of $16.50 million for the quarter, compared to analysts’ expectations of $14.65 million. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%.

Institutional Trading of LENSAR

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNSR. BlackRock Inc. purchased a new position in shares of LENSAR in the 2nd quarter valued at approximately $1,057,000. DCF Advisers LLC purchased a new stake in shares of LENSAR during the second quarter worth approximately $675,000. Man Group plc purchased a new stake in shares of LENSAR during the second quarter worth approximately $445,000. Sanctuary Advisors LLC acquired a new stake in shares of LENSAR during the second quarter worth $96,000. Finally, Groupe la Francaise lifted its holdings in shares of LENSAR by 16.2% during the first quarter. Groupe la Francaise now owns 213,537 shares of the company’s stock worth $1,273,000 after purchasing an additional 29,813 shares during the period. 40.15% of the stock is owned by hedge funds and other institutional investors.

LENSAR Company Profile

LENSAR, Inc is a medical technology company focused on ophthalmic laser systems used in cataract surgery. The company develops femtosecond laser technology designed to assist surgeons with key steps of the procedure, including corneal incisions, lens fragmentation and astigmatism management.

Its product portfolio includes the LENSAR Laser System, an image-guided platform that uses three-dimensional imaging and software-based treatment planning. The system’s capabilities include the company’s Streamline software and IntelliAxis technology, which are intended to support customized treatment planning and the placement of corneal incisions.

LENSAR has marketed its systems to ophthalmic surgeons and health-care providers in the United States and international markets, supported by direct sales and distribution arrangements.